Compare Stocks → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AYLANASDAQ:BCDANASDAQ:ONVONASDAQ:TROV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.48$0.36▼$7.31$7.46M1.9876,300 shs137,700 shsBCDABioCardia$0.38$0.41$0.32▼$2.92$10.10M1.4799,254 shs64,379 shsONVOOrganovo$1.00$1.04$0.89▼$2.05$10.04M0.912.90 million shs116,976 shsTROVCardiff Oncology$4.17-4.4%$16.75$0.70▼$3.46$45.92M1.04648,892 shs702,313 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BCDABioCardia+0.93%+3.10%-6.30%-10.30%-81.03%ONVOOrganovo0.00%-10.71%-2.91%-0.99%-44.13%TROVCardiff Oncology-4.36%-9.15%-28.72%+179.87%+185.62%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABCDABioCardia2.8231 of 5 stars3.35.00.00.02.23.30.0ONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala PharmaceuticalsN/AN/AN/AN/ABCDABioCardia2.50Moderate Buy$4.00954.02% UpsideONVOOrganovoN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M0.00N/AN/A$2.45 per share0.00BCDABioCardia$480K21.24N/AN/A($0.07) per share-5.42ONVOOrganovo$370K27.14N/AN/A$1.76 per share0.57TROVCardiff Oncology$250K183.66N/AN/A$0.94 per share4.44Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ABCDABioCardia-$11.57M-$0.55N/AN/AN/A-2,425.79%-3,638.68%-228.55%5/8/2024 (Estimated)ONVOOrganovo-$17.26M-$2.17N/AN/AN/AN/A-182.88%-138.52%7/11/2024 (Estimated)TROVCardiff Oncology-$16.41M-$2.80N/A∞N/A-3,688.31%-202.00%-122.92%N/ALatest TROV, BCDA, AYLA, and ONVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023BCDABioCardia-$0.11-$0.09+$0.02-$0.09$0.20 million$0.01 million2/8/2024Q3 2024ONVOOrganovo-$0.41-$0.40+$0.01-$0.40$0.08 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28BCDABioCardiaN/A0.400.40ONVOOrganovoN/A3.673.67TROVCardiff Oncology0.122.372.37OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%BCDABioCardia20.57%ONVOOrganovo8.23%TROVCardiff Oncology9.99%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%BCDABioCardia23.90%ONVOOrganovo4.00%TROVCardiff Oncology0.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableBCDABioCardia1626.87 million20.45 millionOptionableONVOOrganovo1810.04 million9.64 millionOptionableTROVCardiff OncologyN/A11.01 millionN/ANot OptionableTROV, BCDA, AYLA, and ONVO HeadlinesSourceHeadlineCardiff Oncology shares surge as first-line colorectal cancer study beginsbioworld.com - March 2 at 9:54 AMCardiff Oncology Stock (NASDAQ:CRDF) Dividends: History, Yield and Datesbenzinga.com - February 23 at 8:35 AMCardiff Oncology’s Onvansertib Shows Promise: An Analysis of the Buy Rating Recommendationmarkets.businessinsider.com - September 29 at 7:51 AMStocks to Watch: MillerKnoll, Cardiff Oncology, Morphic Holdingsmarketwatch.com - September 26 at 8:02 PMCardiff Oncology Shares Up 26% After Potential Cancer Treatment Advancesmarketwatch.com - August 8 at 1:26 PMH.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)markets.businessinsider.com - August 8 at 8:26 AMCardiff Oncology (NASDAQ: CRDF)fool.com - May 27 at 10:27 PMCheap Flights from Cardiff to Bordeauxskyscanner.net - May 15 at 10:11 AMCheap Flights from Cardiff to Corkskyscanner.net - May 2 at 5:42 PMCardiff City FCwalesonline.co.uk - April 29 at 12:09 AMBenetton 27-23 Cardiff: Welsh side's Challenge Cup over after tight affair in Italywalesonline.co.uk - April 25 at 1:30 PMCardiff Oncologyforbes.com - January 13 at 4:28 PMCardiff hostel plagued by drug users and anti-social behaviour goes up for salewalesonline.co.uk - January 11 at 3:27 PMChristmas tree collection dates in Cardiffwalesonline.co.uk - January 11 at 3:27 PMAs Onvansertib fumarate moves closer to clinical approval, what is the likelihood that the drug will be approved?pharmaceutical-technology.com - January 4 at 6:32 AMCardiff Oncology: Staying The Courseseekingalpha.com - December 14 at 9:58 AMCardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updatesfbherald.com - November 4 at 5:22 AMClear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively Buyingmarkets.businessinsider.com - October 16 at 3:13 PMCardiff Oncology, Inc. (CRDF)finance.yahoo.com - September 29 at 6:59 PMCRDF Cardiff Oncology, Inc.seekingalpha.com - September 24 at 9:47 AMCardiff drops its lead prostate cancer program, sending shares into a tailspinendpts.com - September 15 at 6:24 PMLooking Into Cardiff Oncology's Return On Capital Employedmsn.com - August 25 at 1:45 AMCardiff Oncology: Down But Not Outseekingalpha.com - August 22 at 7:24 PMCardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?finance.yahoo.com - July 28 at 1:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeCharles Schwab Fortifies its Uptrend on EPS Beat April 23, 2024 10:15 AMView Charles Schwab Fortifies its Uptrend on EPS Beat 5 Cheap Dividend Stocks: Which to Buy NowApril 1, 2024 9:55 AMView 5 Cheap Dividend Stocks: Which to Buy NowAll Headlines Company DescriptionsAyala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.BioCardiaNASDAQ:BCDABioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Cardiff OncologyNASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.